Your browser doesn't support javascript.
loading
DNA methylation episignature, extension of the clinical features, and comparative epigenomic profiling of Hao-Fountain syndrome caused by variants in USP7.
van der Laan, Liselot; Karimi, Karim; Rooney, Kathleen; Lauffer, Peter; McConkey, Haley; Caro, Pilar; Relator, Raissa; Levy, Michael A; Bhai, Pratibha; Mignot, Cyril; Keren, Boris; Briuglia, Silvana; Sobering, Andrew K; Li, Dong; Vissers, Lisenka E L M; Dingemans, Alexander J M; Valenzuela, Irene; Verberne, Eline A; Misra-Isrie, Mala; Zwijnenburg, Petra J G; Waisfisz, Quinten; Alders, Mariëlle; Sailer, Sebastian; Schaaf, Christian P; Mannens, Marcel M A M; Sadikovic, Bekim; van Haelst, Mieke M; Henneman, Peter.
Afiliación
  • van der Laan L; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Karimi K; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Rooney K; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Lauffer P; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • McConkey H; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Caro P; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
  • Relator R; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Levy MA; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Bhai P; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Mignot C; APHP Sorbonne Université, Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Hôpital Armand Trousseau, Paris, France AND Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, France.
  • Keren B; APHP Sorbonne Université, Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
  • Briuglia S; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
  • Sobering AK; AU/UGA Medical Partnership Campus of the Medical College of Georgia, Athens, Georgia; Windward Islands Research and Education Foundation, True Blue, St. George's, Grenada; St. George's University School of Medicine, Department of Biochemistry, Grenada.
  • Li D; Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA; Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, University of Pennsylvania Perelman school of Medicine, Philadelphia, PA.
  • Vissers LELM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Dingemans AJM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Valenzuela I; Àrea de Genètica Clínica i Malalties Minoritàries, Hospital Vall d'Hebron, Barcelona, Spain.
  • Verberne EA; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Misra-Isrie M; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Zwijnenburg PJG; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Waisfisz Q; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Alders M; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Sailer S; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
  • Schaaf CP; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
  • Mannens MMAM; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Sadikovic B; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada. Electronic address: bekim.sadikovic@lhsc.on.ca.
  • van Haelst MM; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Henneman P; Department of Human Genetics, Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: p.henneman@amsterdamumc.nl.
Genet Med ; 26(3): 101050, 2024 03.
Article en En | MEDLINE | ID: mdl-38126281
ABSTRACT

PURPOSE:

Hao-Fountain syndrome (HAFOUS) is a neurodevelopmental disorder caused by pathogenic variants in USP7. HAFOUS is characterized by developmental delay, intellectual disability, speech delay, behavioral abnormalities, autism spectrum disorder, seizures, hypogonadism, and mild dysmorphic features. We investigated the phenotype of 18 participants with HAFOUS and performed DNA methylation (DNAm) analysis, aiming to generate a diagnostic biomarker. Furthermore, we performed comparative analysis with known episignatures to gain more insight into the molecular pathophysiology of HAFOUS.

METHODS:

We assessed genomic DNAm profiles of 18 individuals with pathogenic variants and variants of uncertain significance (VUS) in USP7 to map and validate a specific episignature. The comparison between the USP7 cohort and 56 rare genetic disorders with earlier reported DNAm episignatures was performed with statistical and functional correlation.

RESULTS:

We mapped a sensitive and specific DNAm episignature for pathogenic variants in USP7 and utilized this to reclassify the VUS. Comparative epigenomic analysis showed evidence of HAFOUS similarity to a number of other rare genetic episignature disorders.

CONCLUSION:

We discovered a sensitive and specific DNAm episignature as a robust diagnostic biomarker for HAFOUS that enables VUS reclassification in USP7. We also expand the phenotypic spectrum of 9 new and 5 previously reported individuals with HAFOUS.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anomalías Múltiples / Enfermedades del Desarrollo Óseo / Anomalías Craneofaciales / Sordera / Trastornos del Neurodesarrollo / Trastorno del Espectro Autista / Discapacidad Intelectual Límite: Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anomalías Múltiples / Enfermedades del Desarrollo Óseo / Anomalías Craneofaciales / Sordera / Trastornos del Neurodesarrollo / Trastorno del Espectro Autista / Discapacidad Intelectual Límite: Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos